Related Experiment Video
Updated: Jul 16, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Management of symptomatic intracranial atherosclerotic disease
Tudor G Jovin1, Rishi Gupta, Michael B Horowitz
1University of Pittsburgh Medical Center, Stroke Institute, 200 Lothrop Street, Suite C-400, Pittsburgh, PA 15213, USA. jovintg@upmc.edu
Insights
Symptomatic intracranial stenosis indicates aggressive vascular disease. While medical therapy is standard, high-risk patients may benefit from endovascular treatment, though further trials are needed.
Area of Science:
- Neurology
- Vascular Medicine
- Interventional Cardiology
Background:
- Symptomatic intracranial stenosis is linked to a high risk of recurrent stroke (approx. 10% per year) and mortality.
- It signifies aggressive vascular disease, often accompanied by comorbidities.
- Medical management, including risk factor control and antiplatelet therapy, is the primary treatment.
Purpose of the Study:
- To review medical treatment options for symptomatic intracranial stenosis.
- To outline the current status of endovascular therapies for this condition.
Main Methods:
- Review of prospective studies on symptomatic intracranial stenosis.
- Analysis of medical treatment strategies.
- Evaluation of endovascular treatment advancements (angioplasty and stenting).
Main Results:
- Certain high-risk patients with severe stenosis (>70%) and hemodynamic impairment may not respond to medical therapy.
- Advances in angioplasty and stenting technologies now allow for endovascular consideration in these refractory cases.
- The comparative benefit of endovascular therapy versus medical therapy for high-risk patients remains to be established in randomized trials.
Conclusions:
- Symptomatic intracranial stenosis requires aggressive management due to its association with poor outcomes.
- Endovascular treatment is a potential option for select high-risk patients refractory to medical therapy.
- Further randomized clinical trials are essential to establish the efficacy of endovascular interventions.
Abstract:
Recently completed prospective studies have shown that with an incidence of recurrent stroke of approximately 10% per year, significant mortality, and other vascular comorbidities, symptomatic intracranial stenosis is a marker of aggressive vascular disease. Although strict control of atherosclerotic risk factors and antithrombotic therapy preferably with antiplatelet agents should be the mainstay of treatment for every patient with this disease, some patients are likely to remain refractory to medical therapy. These high-risk patients appear to be individuals with recent symptoms and severe (> 70%) stenosis with clinical and imaging evidence of hemodynamic impairment distal to the stenotic artery. Advances in balloon and stent technology have made consideration of these high-risk patients for endovascular management with angioplasty and stenting possible, which should ideally take place as part of randomized clinical trials, because the benefit of these high-risk therapies compared with medical therapy is not yet established. This article reviews available medical treatment options for symptomatic intracranial disease and outlines the current state of endovascular therapy for this disease.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Aneurysm III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
